The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer

Abstract excerpt

Epithelial ovarian cancer remains the deadliest gynecologic malignancy. Despite advances in treatment, new approaches are needed. Histone deacetylases (HDACs) are a family of enzymes that regulate gene expression by removing acetyl groups from lysine residues on histones and non-histone proteins. Inhibition of HDACs with small molecules has led to the development of histone deacetylase inhibitors (HDACi) that are...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Histone Deacetylase Inhibitors Research
• Share to Protein Degradation and Inhibitors